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Abstract
Purpose To evaluate the effectiveness of sulodexide for the
treatment of hard exudates (HE) in non-proliferative diabetic
retinopathy (NPDR).
Methods This was a randomized, placebo-controlled, multi-
center trial involving 130 patients (65 for each group) who had
mild-to-moderate NPDR with macular HE. Participants were
given a daily dose of either 50 mg sulodexide or a matching
dose of placebo orally for 12 months. Main outcome measure
was an improvement in HE defined as a decrease in severity
by at least two grades on a 10-grade severity scale. This was
evaluated by fundus photography over 12-month period.
Results The sulodexide group showed significantly greater
improvement in HE severity than that shown by the placebo
group (39.0 % vs. 19.3 %; chi square, P=0.005). Logistic
regression analysis yielded an odds ratio of 2.790 (95 %
confidence interval, 1.155-6.743; P=0.023) for the effect of
treatment once adjustments were made for demographic,
prognostic and disease confounders. Intention to treat and
per-protocol analysis yielded similar results. Sulodexide’s
safety was comparable to that of the placebo.
Conclusions Oral sulodexide therapy over 12 months im-
proved macular HE in patients with mild-to-moderate NPDR,
without leading to detectable adverse events. The study pro-
tocol was registered on clinicaltrial.gov under identifier
NCT01295775.
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Introduction
Diabetic retinopathy is the leading cause of new onset blind-
ness among the working-age group in industrialized countries,
affecting from 2 to 5 % of the entire population [1]. The first
microscopic changes are thickening of the retinal capillary
basement membrane and degeneration of pericytes, both of
which compromise the integrity of the capillary wall, followed
by pericyte loss. Collagen progressively replaces the glycos-
aminoglycans (GAGs) of the basal membrane, leading to
modifications in vascular permeability due to altered anionic
charge. These changes eventually result in the clinical appear-
ance of vascular leakage from the retinal capillaries followed
by microaneurysms. If vascular leakage persists, serum pro-
teins and lipids deposit in the retina and form hard exudates
(HE).
The substitution of GAGs by collagen leads to a basal
membrane thickening also in the kidney. As in the retina,
these changes in permeability of the renal glomeruli induce
the selective loss of proteins, clinically detected as albumin-
uria [2]. It has been suggested that altered GAGmetabolism in
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diabetes patients could be a common pathogenic factor in
diabetic vascular disease [3]. Evidence that both diabetic
retinopathy and nephropathy have a common underlying
pathogenesis (the depletion of GAGs from the basement
membrane) is supported by the findings of the Wisconsin
Epidemiologic Study of Diabetic Retinopathy in which
micro-albuminuria was reported to be cross-sectionally asso-
ciated with retinopathy in diabetes patients [4]. Since current
anti-hyperglycemic therapy cannot fully prevent the compli-
cations associated with diabetes, it is imperative to find new
drugs that can slow or reverse the vascular micro-
abnormalities that ensue.
Sulodexide (Vessel Due F®, Aju Pharm, Seoul, South
Korea, under license from Alfa Wassermann, Bologna, Italy)
is a GAG that consists of heparin and dermatan sulfate, and is
available for oral administration [5]. It has a high trophism for
the vessel wall [6, 7]. Clinical studies have already shown its
efficacy in decreasing micro- and macro-albuminuria in dia-
betes patients, thus suggesting that the partial restoration of
glomerular GAG content might slow the progression of ne-
phropathy [8–13]. Moreover, preliminary observations on the
use of sulodexide in patients with diabetic retinopathy was a
significant reduction in HE, thus indicating a potential benefit
of this GAG at the retinal capillary level [14, 15].
On the basis of these pathophysiological considerations
and experimental findings, we decided to evaluate the effects
of sulodexide on diabetic retinopathy in a double-masked,
randomized, placebo-controlled, multicenter trial: the Diabetic
Retinopathy Sulodexide Study (DRESS). In this phase-2
study, we aimed to assess the effectiveness of sulodexide for
the treatment of HE in non-proliferative diabetic retinopathy




This was a double-masked, randomized, controlled, multicen-
ter study consisting of 130 patients (65 for each treatment arm)
with mild-to–moderate NPDR. Table 1 shows the selection
criteria for the study population. At baseline (T0), ocular
lesions were graded using color fundus photography and
fluorescein angiography (FA). The photographs and FA im-
ages were subsequently sent to a review committee compris-
ing off-site assessors (JH Song, SJ Lim, and HS Chin), who
were unaware of the initial investigators’ assessment. This
committee was nominated to confirm the quality of the images
and the grade of the lesions. After this validation process,
eligible patients were blindly allocated into the following
two groups using a computer-generated list: test (sulodexide)
and control (placebo) groups. Two daily oral dose of
sulodexide 25 mg or the matching placebo were administered
to each patient, one capsule in the morning and one capsule in
the evening, for 360±7 days. The selected dosage regimen for
this study was based on previously published clinical trial data
on sulodexide [7, 9, 11, 12, 16]. Patients were then evaluated
at 3 (T3), 6 (T6), 9 (T9), and 12 months (T12) with a 1-week
window allowed around the follow-up times. This study was
approved by the institutional review board (IRB) and/or the
ethics committee of each participating center, and conducted
in accordance with the Declaration of Helsinki and the guide-
lines on good clinical practice. All participants signed the
written informed consent in the form approved by the relevant
IRB. The study protocol was registered on clinicaltrial.gov
under identifier NCT01295775.
Ophthalmic evaluation
A comprehensive ophthalmic examination was performed
during every visit, including assessment of best-corrected
visual acuity (BCVA) using the Early Treatment Diabetic
Retinopathy Study (ETDRS) protocol; intraocular pressure
(IOP) measurement; slit lamp biomicroscopy; and indirect
ophthalmoscopy. Fundus photography and a contrast sensitiv-
ity test (CST) using the Mars Letter CST (Mars Perceptrix,
Chappaqua, NY, USA), were performed during every visit.
Optical coherence tomography (OCT) and FAwere performed
at T0, T6, and T12. Macular thickness was measured by OCT
(Stratus OCT, Carl Zeiss Meditec, Dublin, CA, USA), and
changes in the mean 1-mm central foveal thickness (CFT)
served to evaluate changes in macular edema.
Efficacy end-points
The primary efficacy endpoint of this study was an improve-
ment of HE, defined as a decrease in HE by at least two
categories of severity. Fundus photography was performed
on fields F1 and F2 (ETDRS Standard), and the HE were
graded according to the specific grading system of this study
which uses an extension of the Airlie House classification,
while FA was performed on seven standard fields (ETDRS
Standard) and graded according to ETDRS [17, 18]. The
grading of HE was based on the area of retina involved and
the amount of HE observed, using ETDRS standard photo-
graphs 3 and 4 for comparison, as follows (Fig. 1);
Grading of hard exudates
Grade 1 Questionable HE
Grade 2 Definite HE; fewer than those in standard photo-
graph 3
Grade 3 HE; as many as those in standard photograph 3
Grade 4 HE; more than those in standard photograph 3, but
fewer than those in standard photograph 4
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Grade 5 HE; more than or as many as those in standard
photograph 4
Since the grade 4 fundus photographs included too wide a
range, it was divided into grade 4a and 4b, which in turn were
divided into “−”, “0”, and “+” grades in order to measure
adequately the changes in HE.
Grade 4a- Very mild deposition of scattered HE but more
than those in standard photograph 3
Grade 4a Mild deposition of scattered HE
Grade 4a+ Mild-to-moderate deposition of scattered HE
Grade 4b- Moderate deposition of HE with any circinate
form
Grade 4b Moderate-to-severe deposition of HE with any
circinate form
Grade 4b+ Severe deposition of HE with any circinate form,
but fewer than those in standard photograph 4
Thus, the fundus photographs yielded a grading of HE that
spanned 10 grades overall (1, 2, 3, 4a-, 4a, 4a+, 4b-, 4b, 4b+, 5)
(Fig. 2). Fundus photographs were graded in a masked fashion
Table 1 Selection of study population
Inclusion criteria Exclusion criteria
Patients aged over 18 years with type 1 or type 2 DM
Diabetes under good control with drugs for at least 6 months (HbA1c <9 %
[75 mmol/mol])
CFT≤300 um of retina by OCT
Snellen visual acuity≥0.4 (20/50)
Mild-to-moderate NPDR assessed by fundus photography and FA
according to Airlie House Classification and ETDRS:
(i) the presence of hard exudates within grade 2 and 5
(ii) at least one of the following lesions: vascular leakages, microaneuryms,
hemorrhages, IRMA
DBP≤90 mmHg and SBP≤130 mmHg with or without medication
Controlled arterial blood pressure for the last 6 months
NPDR which is being treated with laser therapy or should be treated with
laser therapy before the end of the study
Laser therapy or intravitreal injection (anti-VEGF, steroid) within
3 months from enrollment
Concomitant retinal disease due to causes other than diabetic
microangiopathy
Concomitant therapy
(i) antihypertensive treatment, unless administered at stable dosage for at
least 6 months before the start of the study
(ii) ACE inhibitor/ARB therapy, unless administered at stable dosage for at
least 6 months before the start of the study
(iii) warfarin therapy
(iv) hemorrheological, vasoactive drugs and antithrombotics except
acetylsalicylic acid at stable dosage
Severe liver impairment (CHILD C)
Severe renal insufficiency (creatinine >2.2 mg/dl)
Severe cardiac insufficiency (NYHA - New York Heart Association
classes 3 – 4)
Clinical history of diathesis and haemorrhagic disease
Individual hypersensitivity toward the product, heparin, low molecular
weight heparin, or heparin-like products
Intended or ascertained pregnancy or lactation
Participation in a trial within the past 6 months
Surgery or trauma within the past 6 months
Planned surgical intervention within 6 months from enrolment
ACE = angiotensin-converting enzyime, ARB = angiotensin-receptor blocker, CFT = central foveal thickness, DBP = diastolic blood pressure, DM =
diabetes mellitus, ETDRS = early treatment diabetic retinopathy study, FA = fluorescein angiography, IRMA = intraretinal microvascular abnormalities,
NPDR = non-proliferative diabetic retinopathy, OCT = optical coherence tomography, SBP = systolic blood pressure, VEGF = vascular endothelial
growth factor
Fig. 1 The early treatment
diabetic retinopathy study
(ETDRS) standard photographs 3
(a) and 4 (b). From the Early
Treatment Diabetic Retinopathy
Study Research Group (1991);
Grading diabetic retinopathy from
stereoscopic color fundus photo-
graphs – an extension of the
modified Airlie House classifica-
tion. Ophthalmology 98:786–
806. Reprinted courtesy of
Elsevier
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by two independent graders (J. H. S. and S. J. L.) and adjusted
by a third grader (H. S. C.) in cases of disagreement.
The secondary efficacy endpoints encompassed improve-
ments in vascular leakage; microaneurysms; hemorrhages;
intraretinal microvascular abnormalities at FA, BCVA, IOP
and CFT as detected by OCT, and CST.
Safety endpoints
Vital signs were monitored during each visit while hematolo-
gy and clinical chemistry were examined at T0 and T12 visits.
The laboratory safety tests included tests for the following: red
blood cell count (RBC); white blood cell count (WBC) with
differential count; platelets; hematocrit (Hct); hemoglobin
(Hb); erythrocyte sedimentation rate (ESR); blood creatinine
level; aspartate aminotransferase (AST) level; alanine amino-
transferase (ALT) level; gamma glutamyltransferase (γGT)
level; blood fibrinogen level; activated partial thromboplastin
time (aPTT); and lipid panel. We also monitored fasting blood
glucose and glycosylated hemoglobin (HbA1c) during each
visit. Lastly, possible adverse effects of treatment were mon-
itored by investigators who questioned the patient during each
visit and on the final day of assessment.
Study populations
Figure 3 reports patients’ dispositions. The primary test pop-
ulation was the intention-to-treat (ITT) population, which
included all patients who were randomized to treatment, re-
ceived the medication they had been randomized to, and had
both valid baseline and 12-month fundus photography. The
secondary test population was the per-protocol (PP)
population, which included all patients of the ITT population
who, in addition to this, complied with all the inclusion and
exclusion criteria and took at least 80 % of the planned
treatment doses. The safety population included all the 127
patients who participated in the trial, who received the med-
ication they had been randomized to, and who were seen at
least once by the attending physician (Fig. 3).
Statistical methods
The primary variable was an improvement of HE in NPDR
that was defined in this study as a decrease in HE by at least
Fig. 2 Typical examples of fundus photographs in each grade. a Grade 2. b Grade 3. c Grade 4a-. d Grade 4a. e Grade 4a+. f Grade 4b-. g Grade 4b. h
Grade 4b+
Fig. 3 Patients’ dispositions. ITT = intention to treat, PP = per protocol
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two points on the grading scale. Based on the existing litera-
ture, it is estimated that such a decrease could spontaneously
occur in approximately 20–30 % of the patients, thus
reflecting known fluctuations that exist in the severity of
background retinopathy. The study design was consistent with
the choice of a two-tailed, chi-square test for significant dif-
ferences between proportions. An accepted level of signifi-
cance was P≤0.05, with a wanted power of 90 %. Using a
sample size of 56 patients per group, the study would have had
a power of 90.2 % to yield statistically significant results
under the conditions expressed above. In order to account
for non-assessable cases and for randomization in blocks,
the sample size was increased to 65 patients per group. Chi-
square test was accompanied by a relative risk estimate of the
proportion of improved patients in the ITT population. To
exclude any effect associated with demography, history, and
progress of underlying diabetes, the rate of success was also
analyzed using binary multivariable logistic regression analy-
sis. The following were included among the putative predic-
tors: baseline HE severity (≤4a/>4a); number of affected eyes;
age (<60/≥60 years); sex; body mass index (BMI) (<25/≥25);
diabetes duration (<10/≥10 years); as well as the changes -
estimated with the last observation carried forward procedure
and coded as decreased vs. unchanged or increased - in blood
glucose, Hb1Ac, total cholesterol, high density lipoprotein
(HDL), low density lipoprotein (LDL), and triglycerides
(TG). These analyses were also performed on the PP
population.
The secondary efficacy endpoints were only analyzed only
in the ITT population.
The safety analysis, performed on the safety group, moni-
tored the following: the course of adverse events, laboratory
data, vital signs, and changes in physical examination. All
analyses were performed using the Statistical Package for the




There was no evidence of clinical or statistical differences in
demographic profile, history of DM, and general or specific
medical history, among the treatment groups (Table 2), with
the exception of concomitant medications in use (test group,
86.44 %; control group, 70.18 %; P=0.0332). In detail, 91 of
116 patients the in ITT population have administered combin-
ing drugs and the major differences between treatment groups




Success, which was defined as an improvement in hard exu-
dates by at least two categories of the severity, was seen in
39.0 % of the affected eyes among the treated patients (95 %
confidence interval [CI], 28-50 %) compared to 19.3 %
among control patients (95 % CI, 6–33 %). This difference
was statistically significant (chi square test,P=0.005; Table 3).
This yields a number needed to treat of five (95 %CI, 3–16) to
obtain one success more with the tested treatment, in compar-
ison with the standard of care alone. Figure 4 illustrates two
paradigmatic cases recorded under treatment (Fig. 4).
The logistic regression yielded an odds ratio (OR) of 2.790
(95 % CI, 1.155–6.743; P=0.023) for the effect of treatment
once adjustments were made for demographic, prognostic and
disease confounders, as described in Table 4. The analysis also
confirmed some clinically known effects (Table 4). When
both eyes were affected, the chance of success was lower
(OR 0.430; 95 % CI, 0.190–0.969; P=0.042). Increased cho-
lesterol reduced the chances of success (OR 0.311; 95 % CI,
0.103–0.940; P=0.039), while increased HDL had an oppo-
site effect (OR 2.458; 95 % CI, 1.045–5.780; P=0.039).
The PP population yielded almost identical results to the
ITT population (Table 3), with a success rate of 38.9 % in
treated patients compared to 17.6 % in control patients (P=
0.005). In this population the logistic regression analysis
(Table 4) confirmed the significant treatment effect (OR
4.062, 95 % CI, 1.432–11.523; P=0.008) as well as the
favourable effect of decreased cholesterol and increased/
unchanged HDL.
Secondary efficacy variables
None of the tested secondary efficacy variables (FA, BCVA,
IOP, CFT, and CST) yielded statistically significant differ-
ences between the treatment groups.
Safety analysis
Overall, 18 out of the 127 patients in the safety population
(14.17 %) reported 32 adverse events: seven out of 63 patients
in the treatment group (11.11 %) reported 17 reactions; and 11
out of 64 patients in the control group (17.19 %) reported 15
reactions. The proportion of patients with adverse events was
not significantly different between treatment groups (chi
square, P=0.3263). One treatment patient and two control
patients reported potential treatment-related adverse events,
all gastrointestinal in nature. One control patient reported a
severe event of angina, which was classified as definitely not
associated with the assigned treatment.
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There were no statistically or clinically relevant evidence of
differences between treatment groups with regards to the
course of vital signs and laboratory tests.
Discussion
Diabetic retinopathy is a microvascular complication that
primarily affects capillaries, which results in damage to retinal
vascular endothelium, leading to leakage and ischemia. Sub-
sequent visual loss is due to the occurrence of hemorrhages,
HE, macular edema, and retinal detachment. There are cur-
rently several treatment options available for diabetic retinop-
athy, but no definitely established pharmacological approach
has been defined.
Sulodexide is a highly purified GAG with a high affinity
for anti-thrombin III, heparin cofactor II, and vascular endo-
thelium [6, 7, 19, 20]. Preliminary observations of patients
with diabetic retinopathy that were treated with sulodexide
have indicated significant reductions in HE, thus highlighting
a potential benefit at the retinal capillary level [14]. Moreover,
the incidence and severity of adverse events associated with
sulodexide was reported to be no different than those of the
placebo group, even at high doses, although mild gastrointes-
tinal upsets were reported [9, 21, 22].
The DRESS research was designed to assess the effective-
ness of sulodexide in the treatment of HE in NPDR in type 1
and type 2 DM patients. Vascular complications of DM are
generally accompanied by development of endothelial dys-
function or injury, and in experimental models, this endothe-
lial dysfunction or injury is manifested by an increased num-
ber of circulating endothelial cells. In vitro and animal models
(rats with streptozotocin-induced diabetes) of endothelial
injury/dysfunction have reported that sulodexide was able to
repair or prevent the endothelial damage, lower the number of
circulating endothelial cells, and improve the endothelium-
dependent relaxation of small arteries [23–25]. Recently, it
was proved that oral sulodexide administration in patients
with type 2 DM enhances the availability of precursors for
GAG synthesis, thereby improving the endothelial glycocalyx
dimension in sublingual and retinal vascular beds. Sulodexide
also helped normalization of systemic vascular permeability
and GAG metabolism [7].
Table 2 Baseline characteristics
Variable Test (n=59) Control (n=57) P
Gender women, n (%) 29 (60.4 %) 19 (39.6 %) 0.084*
Age (yrs) mean ± std 59.1±8.7 59.9±10.6 0.893†
BMI (kg/m2) mean ± std 23.78±2.98 23.91±2.95 0.827†
Diabetes duration (yrs) mean ± std 15.4±8.7 14.2±7.5 0.441†
History of other diseases yes, n (%) 31 (52.5 %) 29 (50.9 %) 0.858*
History of retinopathy yes, n (%) 57 (96.6 %) 53 (93.0 %) 0.260‡
Previous treatments yes, n (%) 5 (8.5 %) 1 (1.8 %) 0.207‡
Concurrent treatment yes, n (%) 51 (86.4 %) 40 (70.2 %) 0.033*




Table 3 Proportion of success
Population Control n (%) Test n (%) Total n (%) Chi square
ITT
Success 16 (19.3 %) 32 (39.0 %) 48 (29.1 %)
Failure 67 (80.7 %) 50 (61.0 %) 117 (70.9 %) 7.798; P=0.005
Total eyes 83 82 165
PP
Success 12 (17.6 %) 28 (38.9 %) 40 (28.6 %)
Failure 56 (82.4 %) 44 (61.1 %) 100 (71.4 %) 7.732; P=0.005
Total eyes 68 72 140
ITT = intention-to-treat, n = number of eyes, PP = per-protocol
834 Graefes Arch Clin Exp Ophthalmol (2015) 253:829–837
In this double-masked, randomized, multicenter study, ef-
ficacy analysis was performed on a total of 165 eyes in the ITT
population and a total of 140 eye in the PP population. The
primary endpoint of this study, and defined as an improvement
Fig. 4 Fundus photographs of
two subjects in sulodexide group.
a At T0, fundus photograph
showed grouped hard exudates
graded as 4b-. b Hard exudates
gradually decreased to grade 3 at
T6. c Further diminution of hard
exudates attained grade 2 at T12.
d Funds photograph of another
subject revealed grouped hard
exudates of grade 4b- at T0. e
This patient also showed im-
provement in hard exudates to
grade 4a at T6. f Further im-
provement continued to reach
grade 3 at T12
Table 4 Results of the multivariable logistic regression analysis for the outcome “success”

































































































BMI = body mass index, CI = confidence interval, HbA1c = glycosylated hemoglobin, HDL = high density lipoprotein, ITT = intention-to-treat, LDL =
low density lipoprotein, OR = odds ratio, PP = per-protocol
* Change in the 12-month observation, estimated with the last observation carried forward procedure
† Increased set includes cases of unchanged values
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in HE by two categories of severity, was significantly greater
among patients receiving sulodexide compared to the control
group, both in the ITT and PP populations. In addition to the
significant treatment effect, our study displayed a significantly
negative effect of high cholesterol and a significantly positive
effect of HDL. Other variables reported to be clinically related
to changes in the severity of HE, namely blood glucose,
HbA1c, LDL, and TG, were not found to be significant
predictors of success or failure in this study. This study also
showed a favorable safety profile of sulodexide.
The trial recruited diabetes patients with only mild-to-
moderate retinopathy and relatively good vision, and hypoth-
esized that sulodexide could be effective at the early phases of
exudation, when permanent damage to the vessel wall has not
yet occurred. In the presence of permanent organ damage,
other metabolic pathways and new pathologic factors such as
vascular endothelial growth factor (VEGF) might become
activated, which may not respond to the pharmacodynamics
of sulodexide. None the less, further investigation of its use in
patients with more severe diabetic retinopathy and/or low
vision due to macular edema is required. If the results are
positive, sulodexide may act as an adjunctive treatment to
laser therapy or anti-VEGF agents, which are the current
treatment standard.
Although an improvement in HE was significantly greater
in the suldoexide group compared to the control group, about
60 % of patients receiving sulodexide did not react to the
treatment. It might be partly due to the low dose of study drug
and the limited duration of treatment. This study used the
lowest daily dose of sulodexide, because of the safety issue.
Another explanation for this result might be the limited effect
of sulodexide on vessel wall. Sulodexide is postulated to have
its beneficial effect on retinal capillary by partial restoration of
GAG content. The vascular leakage, resulting in HE, in a
diabetic retinopathy is also caused by some other factors,
e.g. loosening of endothelial tight junctions induced by
VEGF. The use of sulodexide could have decreased the vas-
cular leakage by supplementing GAGs of capillary basement
membrane and correcting altered anionic charge. However,
there were still other pathogenic factors increasing vascular
permeability and not influenced by sulodexide treatment.
These might have resulted in partial response to sulodexide.
One of the limitations of this study is the relatively high
proportion of ITT patients, 25 out of 116, who did not com-
plete the study according to protocol (Fig. 3). However, we
consider it unlikely that this introduced a substantial bias in
the evaluation of the drug effect, since the ITT and PP results
were comparable, and the proportion of patients and reason
for exclusion were very similar between the two treatment
groups.
Another limitation is that the dose of sulodexide used in
this study has not been validated for the management of
diabetic retinopathy. We selected the 50 mg daily dose, a
common regimen used in clinical practice that has also been
reported in several published clinical trials, mainly for precau-
tionary reasons given the long duration of treatment (1 year).
Other studies in diabetes patients used higher doses (100–
400 mg per day); however, the duration of treatment in these
cases was significantly shorter (4–6 months) [9, 11, 14, 16,
26]. Considering the safety of sulodexide observed in this
study, a higher daily dose should be used in any subsequent
long-term evaluations of this drug in patients with diabetic
retinopathy.
In conclusion, the results of our study indicate that the use
of sulodexide, a natural GAG with complex effects on the
vascular wall, effected a decrease in macular HE in patients
with mild-to-moderate NPDR and the sulodexde treatment
group showed significantly greater improvement in HE sever-
ity than that shown by the placebo group. However, further
and probably larger long-term studies are warranted, possibly
with higher dosages, to confirm whether the treatment with
sulodexide has a sustained beneficial effect on NPDR.
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